Non-invasive liver diagnostics via quantitative MRIprimary
4 projects
Core technology in Paediatric LMS, RADIcAL, LITMUS, and MAST4HEALTH — all focused on MRI-based liver assessment without biopsy.
Organization
PERSPECTUM LTD
Oxford SME developing non-invasive MRI-based liver diagnostics (LiverMultiScan) for NAFLD, chronic liver disease, and paediatric obesity.
Technology SMEhealthUKSMENo active H2020 projects
H2020 projects
5
As coordinator
2
Total EC funding
€4.2M
Unique partners
86
What they do
Their core work
Perspectum is an Oxford-based medical technology SME that develops non-invasive diagnostic tools for liver disease, built on quantitative magnetic resonance imaging (MRI). Their core product, LiverMultiScan, enables clinicians to assess liver health — including fat, iron, and fibrosis — without biopsy. Across their H2020 portfolio, they apply this MRI-based diagnostic platform to populations ranging from obese children (Paediatric LMS) to adults with non-alcoholic fatty liver disease (RADIcAL, LITMUS), and contribute imaging expertise to broader radiomics and personalized medicine initiatives (PREDICT).
Core expertise
What they specialise in
NAFLD and NASH biomarker developmentprimary
3 projects
LITMUS explicitly targets steatohepatitis biomarkers; RADIcAL and MAST4HEALTH address chronic liver disease and NAFLD in obese populations.
Radiomics and medical image analysissecondary
1 project
PREDICT project applies radiomics as a decision-support tool for diagnostics and theragnostics across disease areas.
Paediatric obesity and liver healthsecondary
1 project
Paediatric LMS specifically adapted their MRI platform for obese children, a distinct clinical population.
Clinical validation and regulatory pathway for medical devicesemerging
2 projects
RADIcAL (EUR 3.5M, coordinated) and LITMUS represent large-scale clinical validation efforts needed for regulatory approval and market adoption.
Evolution & trajectory
How they've shifted over time
Early focus
Paediatric liver MRI product development
Recent focus
NAFLD biomarkers and radiomics
Perspectum entered H2020 in 2015 with early-stage SME instrument funding (Phase 1) for a focused paediatric liver MRI application, then rapidly scaled to coordinating RADIcAL — a EUR 3.5M Phase 2 project for broader chronic liver disease assessment. By 2017, their participation shifted toward large multi-partner research consortia (LITMUS, PREDICT) focused on NAFLD biomarkers and radiomics, indicating a move from product development toward clinical validation and integration into wider diagnostic ecosystems.
Perspectum is transitioning from a single-product MRI diagnostics company toward a broader platform player in liver disease biomarkers and AI-driven medical imaging, making them increasingly relevant for precision medicine and digital health consortia.
Collaboration profile
How they like to work
Role: specialist_contributorReach: European20 countries collaborated
Perspectum operates as both a project leader and a specialist contributor. They coordinated two SME Instrument projects (Phases 1 and 2) where they drove the agenda, while also joining large research consortia like LITMUS (multi-year, multi-partner NAFLD study) as an imaging technology provider. With 86 unique partners across 20 countries, they are well-networked for an SME and comfortable working in both small focused teams and large international consortia.
Perspectum has built a notably wide network for a small company — 86 unique consortium partners across 20 countries. Their reach spans well beyond the UK, with strong connections into European clinical research networks through health-focused consortia like LITMUS and PREDICT.
Why partner with them
What sets them apart
Perspectum occupies a rare niche: they are one of very few SMEs that both develop and clinically validate a proprietary non-invasive liver diagnostic platform within EU-funded research. Their LiverMultiScan technology gives them a concrete, commercializable asset — not just research output — which makes them a strong partner for consortia needing real-world diagnostic tools rather than theoretical contributions. Their SME Instrument trajectory (Phase 1 to Phase 2) demonstrates proven ability to translate research into market-ready products.
Notable projects
Highlights from their portfolio
- RADIcALLargest project by far (EUR 3.5M, SME Phase 2) — Perspectum coordinated this clinical validation of their LiverMultiScan technology for chronic liver disease.
- LITMUSMajor multi-year NAFLD biomarker consortium (2017-2024) where Perspectum contributed MRI-based endpoints, connecting them to Europe's leading liver research groups.
- PREDICTExtends Perspectum's imaging expertise into radiomics and personalized medicine, signaling expansion beyond liver-specific applications.
Cross-sector capabilities
Medical imaging and AI-driven diagnosticsDigital health and clinical decision supportPaediatric health and obesity researchPersonalized medicine and radiomics
More in Health & Biomedical
See all Health & Biomedical organizations →KOBENHAVNS UNIVERSITET
Denmark's largest research university, excelling in genomics, CRISPR, microbiome science, ancient DNA, and climate research across 696 H2020 projects.
Open →
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France's national biomedical research agency — 400+ H2020 projects spanning neuroscience, infectious disease, cancer, and omics-driven diagnostics.
Open →
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany's leading research university in molecular biosciences and translational medicine, with 303 H2020 projects and exceptional ERC grant concentration.
Open →